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MATRICS Cognitive Consensus Battery (MCCB)The UCSD Performance-based Skills Assessment Brief (the UPSA-B) has been widely used for evaluating functional
capacity in patientswith schizophrenia. The utility of the battery in awide range of cultural contexts has been of con-
cern among developers. The current study investigated the validity of the Japanese version of the UPSA-B as amea-
sure of functional capacity and as a co-primary for neurocognion. Sixty-four Japanese patients with schizophrenia
and 83 healthy adults entered the study. The Japanese version of the UPSA-B (UPSA-B Japanese version) and the
MATRICS Cognitive Consensus Battery Japanese version (MCCB Japanese version) were administered. Normal con-
trols performed signiﬁcantly better than patients, with large effect sizes for the Total and the subscale scores of the
UPSA-B. ReceiverOperating Characteristic (ROC) curve analysis revealed that the optimal cut-off point for theUPSA-
B Total score was estimated at around 80. The UPSA-B Total score was signiﬁcantly correlated with theMCCB Com-
posite score and several domain scores, indicating the relationship between this co-primary measure and overall
cognitive functioning in Japanese patients with schizophrenia. The results obtained here suggest that the UPSA-B
Japanese version is an effective tool for evaluating disturbances of daily-living skills linked to cognitive functioning
in schizophrenia, providing an identiﬁable cut-off point and relationships to neurocognition. Further research iswar-
ranted to evaluate the psychometrical properties and response to treatment of the Japanese version of the UPSA-B.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
There has been a growing concern over functional outcome in pa-
tients with schizophrenia (Burns and Patrick, 2007) since its inclusion
in DSM-III or later editions. Functional outcome refers to a wide range
of real-world functioning including residential independence, employ-
ment, daily-living skills (e.g. ﬁnancial management, telephone commu-
nication), or social activities (Harvey and Bellack, 2009). The role of
cognitive deﬁcits in impaired functional outcome has been well-
conceptualizedwith the advent of theMeasurement and Treatment Re-
search to Improve in Schizophrenia Consensus Cognitive Battery
(Nuechterlein and Green, 2006; Nuechterlein et al., 2008). Although
the initial purpose of theMCCBwas to provide a comprehensive battery
sensitive to neurocognitive improvement by drug treatment, co-
primary measures, predictive of real-world functioning, were also. Sumiyoshi).
. This is an open access article underrequested to accommodate the development of cognitive enhancers
(Buchanan et al., 2011).
Performance-based batteries such as the UCSD Performance-based
Skills Assessment-Brief (Mausbach et al., 2007) have been shown to pro-
vide a potential co-primary measure, satisfying 1) test–retest reliability,
2) a moderate practice effect, 3) a high completion rate, 4) a good corre-
lationwith neurocognitive performance, and 5) a discriminability for res-
idential status and social involvement, such as work (Leifker et al., 2009,
2010; Mausbach et al., 2007, 2008, 2011; Olsson et al., 2012).
As the name suggests, tasks in the UPSA-B are role-played using props
(e.g. money, an invoice, a letter, and a telephone etc.) to evaluate func-
tional capacity (competence) in daily-living contexts (Mausbach et al.,
2007, 2011). Thebattery consists of two subscales: Finances (e.g. counting
money, bill payment) and Communication (e.g. using a phone). They
were extracted from the full version of the original UPSA (Patterson
et al., 2001) based on factor analysis (Mausbach et al., 2007). Due to its
conciseness (approximately 10–15 min) and effectiveness as a co-
primary measure, the battery has been widely used in the US, and has
been introduced in Europe (Sweden: Harvey et al., 2009a; Olsson et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
The UPSA-B studies in the US and other countries.
Country Study Participantsa N UPSA-Bb Samplec
Total Finances Communication
US Bowie et al.,
2010
SCZ 161 69.9 – – Patients with schizophrenia or schizoaffective disorder
who were community living with Ashkenazi Jewish backgrounds.
Results were obtained from the analyses of subsamples
BD 130 88.5
Green et al.,
2011
SCZ 162 73.0 – – Recruited at the Validation of Intermediate Measure (VIM) study
under the MATRICS initiative
Harvey et al., in
press
SCZ 3445 74.0 – – Enrolled in the genomic study based on a Veterans Administration
initiative (CSP#572)BD 4624 83.0
Keefe et al.,
2011
SCZ 323 70.0 – – Participants were in a large multi-site trial assessing the comparative
effects of antipsychotic treatment with lurasidone or risperidone
Leifker et al.,
2009
SCZ 194 72.2 – – Older patients with schizophrenia enrolled in longitudinal study
of the course of cognitive and functional status. They were recruited
at Mt. Sinai School of Medicine or other hospitals
Leifker et al.,
2010
SCZ (Mt. Sinai) 238 68.7d – – Part of data was from Leifker et al., 2009
SCZ (UCSD) 116 56.5 Recruited from Board and Care facilities in San Diego who enrolled in
Functional Adaptation Skills Training
NC 109 84.5 Healthy subjects recruited at a naturally occurring retirement
community (NORC) in Manhattan
Mausbach
et al., 2007
Independent
living SCZ
99 72.5 – – Recruited at the UCSD Advanced Center for Interventions and Services
Research. A subset of participants was part of the Functional Adaption
Skills Training
(FAST) study (Patterson et al., 2006)
Non-independent
living SCZ
335 54.5
Mausbach
et al., 2008
Assisted-living, SCZ,
Schizoaffective
163 53.9 – – Part of data was from the FAST study
Community-living SCZ,
Schizoaffective
73 54.7
China McIntosh et al.,
2011
SCZ (Chinese) 272 37.6 – – Inpatients treated at a municipal psychiatric hospital in Beijing
BD (Chinese) 61 55.2
Major depression
(Chinese)
50 47.9
NC (Chinese) 284 64.3
India Velligan et al.,
in press
SCZ (Indian) 160 67.6 – – Recruited from 6 different sites recommended by the MATRICS
Scientiﬁc Advisory Board
US Harvey et al.,
2011
SCZ (Atlanta Skyland
Trail)
55 75.5 Enrolled in the Validation of Everyday Real-World Outcomes
(VALERO) study (Harvey et al., 2011, 2013)
SCZ (Atlanta VA
Medical Center)
40 81.7 40.1 –
Harvey et al.,
2013
SCZ (UCSD Outpatients
Psychiatric Services)
100 75.3
Burton et al.,
2013
SCZ, Schizoaffective 183 40.0 36.4 Data from the three different services referred in the VALERO study
(Harvey et al., 2011, 2013)
Harvey et al.,
2009b
SCZ, Schizoaffective 236 68.8 – – Schizophrenia or schizoaffective participants in a longitudinal study
of cognitive and functional status. Outpatients recruited from several
sites in New York and its suburbs
Harvey et al.,
2009a
SCZ 244 37.4 31.5 Data from the same general data set in Harvey et al., 2009a,b
Mausbach
et al., 2010
SCZ 116 75.6 39.5 36.1 Data from the same resource in Bowie et al., 2010
BD 89 88.7 45.7 43.0
Mausbach
et al., 2011
SCZ 367 77.5 41.1 36.4
Sweden Harvey et al.,
2009a
SCZ (Swedish) 146 68.9 38.7 30.9 Outpatients recruited at a country council-founded clinic at NU
Health Care Hospital
Olsson et al.,
2012
SCZ, Schizoaffective,
Delusional (Swedish)
211 69.4 38.8 30.6 Participants were in the study of Clinical Long-term Investigation of
Psychosis in Sweden (CLIPS)
Denmark Vesterager
et al., 2012
First episode
SCZ (Danish)
117 77.5 40.2 37.3 Participants were in the multi-site randomized clinical trial for
cognitive remediation program (the NEUROCOM trial)
a SCZ: schizophrenia, BD: bipolar disorder, NC: normal controls.
b MAX score: Total = 100, Finances = 50, Communication = 50.
c Patients were mostly outpatients except for McIntosh et al., 2011.
d A base line score.
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2011; India: Velligan et al. in press) (Table 1). Also, the Japanese version
(Sumiyoshi et al., 2011) is under standardization.Although the UPSA-B has promise for assessing functional capacity,
some issues remain under consideration in developing its Japanese ver-
sion. First, the normative performance on the Japanese version needs to
139C. Sumiyoshi et al. / Schizophrenia Research: Cognition 1 (2014) 137–143be clariﬁed. To date, several studies have presented data of a normal
population (Leifker et al., 2010; McIntosh et al., 2011). According to
these reports, the achievement of the normal samples ranges from 60
to 85 (Table 1), which may be affected by age and educational attain-
ment. The study with the US samples (Leifker et al., 2010) presented
scores of elderly healthy people (themean age= 68.0)with large effect
sizes between schizophrenia patients (d = 0.90–1.58 across multiple
sites). On the other hand, Chinese control subjects who had relatively
low levels of average educational attainment (Mean= 8 years) elicited
a considerably lower score (64.3) (McIntosh et al., 2011), while the dis-
association from normal controls (d = 1.08) was the same degree as
that in the US study (Leifker et al., 2010).
The normative performance differentiating between normal and
clinical samples can also be discussed from the view point of indepen-
dency of living. The initial development study of the UPSA-B
(Mausbach et al., 2007), examined a cut-off point classifying patients
with schizophrenia into independent- versus non-independent living
groups. A score of around 60 was estimated as the optimal cut-off, sug-
gesting that patients above that have the capacity to live independently
as a part of the normal population. Given the ratherwide range of scores
of the achievement related to the standard, an optimal cut-off point, dif-
ferentiating normal subjects from patients, needs to be determined for
the Japanese version of the UPSA-B. Speciﬁcally, data from relatively
younger (30–50 years old) normal samples are of concern, which has
not been addressed in previous studies.
Second, the possible inﬂuence of the cultural or socio-economical
backgrounds needs to be considered. Cross-cultural adaptability of func-
tional outcome measures including the UPSA-B has been discussed
among its developers (Gonzalez et al., 2013; Harvey and Velligan,
2011; Velligan et al., 2012). Ratings by experts in different countries in-
cluding Europe, Russia, and Asia resulted in a relatively poorer cultural
adaptability of theUPSA-B compared to the case in theUS, dueprobably,
to the difference in daily-living standards. Speciﬁcally, Mexico, India,
and China presented the greatest challenges in adaptation (Velligan
et al., 2012). On the other hand, theUPSA-Bmay bewell accommodated
in countries with relatively uniformly westernized living environments
like Japan.
Third, the Japanese version of the UPSA-B is expected to serve as an
effective co-primary measure for standard neurocognitive batteries
such as theMCCB, as shown by previous studies (Green et al., 2011). Ac-
cordingly, the correlation with cognitive functioning needs to be evalu-
ated as part of the development of the UPSA-B_J.
The purposes of the current study were to address those issues in
showing the utility of the UPSA-B in Japan. First, the performance on
the UPSA-B was compared between young or middle-aged normal con-
trols and patients with schizophrenia. A cut-off point differentiating nor-
mal controls from patients was also determined. In addition, proﬁles ofTable 2
Characteristics of participants.
NC SCZ Effect
N (M/F) 83 (71/12) 64 (34/30) –
Age 34.6 (9.4)b 35.2 (11.2) –
Education 16.6 (1.1) 13.6 (2.4) –
Duration – 9.7 (8.1) –
Drug (mg)c – 444.8 (492.0) –
BPRS_Positive – 10.0 (5.9) –
BPRS_Negative – 7.5 (3.4) –
BPRS_Total – 36.5 (12.8) –
MCCB Composite 510.5 (47.3) 376.3 (76.0) 2.1
UPSA-B Total 82.1 (8.6) 69.5 (13.7) 1.1
Finances 48.7 (3.3) 43.8 (7.8) 0.8
Communication 33.4 (7.6) 25.7 (9.5) 0.9
NC: normal controls, SCZ: patients with schizophrenia.
a Cohen's d for normal controls vs. patients.
b Mean (SD).
c CPZ equivalent.the task performance were produced to see if the domain- and task-
speciﬁc difﬁculties exist in both groups. Finally, the relation to
neurocognitive functioning, as assessed by the MCCB-J, was investigated
to conﬁrm its validity as a co-primary measure.
2. Methods
2.1. Participants
Sixty-four Japanese patients with schizophrenia and 83 healthy
adults entered the study. Demographic and clinical proﬁles of the partic-
ipants are summarized in Table 2. Patients were outpatients treated in
Okayama University Hospital, and public or private hospitals in Toyama
Prefecture. Diagnosis was established based on the DSM-IV-TR criteria
by experienced psychiatrists using a structured interview, reference to
medical history, and all available information. Patients known to be
abusing alcohol or illicit drugs, or those with epilepsy, brain damage,
or neurologic disorders, were excluded from the study. Psychiatric
symptoms were assessed on the Brief Psychiatric Rating Scale (BPRS),
18-item version (Overall and Gorham, 1962).
Normal controls were recruited at Okayama University. The
majority of them were ofﬁce employees working in Okayama Prefec-
ture. Written informed consent was obtained from all participants.
The study protocolwas approved by ethics committees at the respective
study sites.
2.2. Measures
The Japanese versions of UPSA (Sumiyoshi et al., 2011) and MCCB
were administered to all participants. The UPSA-B Japanese version
was developed based on the international version of the UPSA-B, with
some modiﬁcations to adjust for differences in everyday functional de-
mands in Japan. It has been approved by developers after conducting
two independent forward and back translations, reconciliation, and
pilot testing on patients. The MCCB Japanese version has been shown
to have good psychometric properties and validity (Kaneda et al., 2013).
Subscale scores of the two domains of the UPSA-B (i.e. Finances,
Communication) were converted into the standard score ranging from
0 to 50, and thus the maximum of the Total score was 100 (Mausbach
et al., 2007). Raw scores for the 10 subtests of theMCCBwere converted
to T-scores (mean = 50, SD = 10), out of which the seven domain
scores were produced (Nuechterlein and Green, 2006). The T-score of
each task corresponds to the domain score except for Speed of Process-
ing (TMT, BACS SC, and Fluency) andWorkingMemory (LNS andWMS-
SS), for which the composite scores were calculated by summing to the
T-scores of tests included in those domains. The overall composite scoresizea t/F (df) p Interpretations
t = −0.13 (143) 0.72 NC = SCZ
t = 10.12 (143) b0.000 NC N SCZ
–
–
–
–
–
F = 67.30 (1,140) b0.000 NC N SCZ
t = 6.80 (145) b0.000 NC N SCZ
F = 46.24 (1,145) b0.000 NC N SCZ
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and Green, 2006).
The formal Japanese version of the MCCB was not released at that
moment, and thus, the T-scores of the Japanese version were produced
based on the data obtained in a preliminary study for the development
of the Japanese version; the normative group consisted of 85 healthy
adults (mean age =40.0, SD = 11.2, range 19–65) and the mean and
the standard deviation of this group served as the reference for the T-
score conversion. Age-correction was applied according to the regres-
sion method employed in the standardization study in the US (Kern
et al., 2008). Although both age- and gender-corrections are recom-
mended in the MCCB Manual (Nuechterlein and Green, 2006), only
the former was applied due to limitations in the reference group at
that moment.2.3. Statistical analyses
SPSS ver. 17.0 (SPSS Inc.) was used for all the analyses except for the
estimation of effect sizes.2.4. Group comparisons
Demographic variables (age and education) and the UPSA-B Total
score were compared by t-test. Two-way analysis of variance (Two-
way ANOVA) was conducted for the group comparisons for the UPSA-
B subscales with Group (normal controls vs. patients) as a between-
subject factor while Subscale (Finances vs. Communication) as a
within-subject factor. The MCCB composite score was compared by
one-way analysis of covariance (ANCOVA) controlling education. Effect
sizes (Cohen’s d) were calculated by dividing the mean difference be-
tween normal controls and patients by a pooled SDs from the
two groups.Total score (MAX=100)
Cut-off=77.8
d ’=1.26
1.0
0.82.5. ROC curve analyses
Receiver Operating Characteristic (ROC) curves analyses were con-
ducted for the UPSA-B Total and subscale scores. Every possible cut-
off point was speciﬁed at a speciﬁc sensitivity and 1− speciﬁcity. Sen-
sitivity corresponds to the ‘hit’ rate indicating the correct classiﬁcation
of normal subjects as a normal sample. 1− speciﬁcity and speciﬁcity
represent the ‘false alarm (FA)’ and ‘correct rejection (CR)’ rates, respec-
tively. The former refers to the rate of misclassifying patients into the
normal sample, while the lattermeans the rate of correctly determining
patients. As for the measure of sensitivity, the area under curve (AUC)
with the 95% conﬁdential interval (95% CI) and d’ (d-prime)
(Gescheider, 1985) were calculated; larger values suggest better
sensitivity. Optimal cut-off points were determined for the UPSA-B
Total score, at which the sum of sensitivity (% of hit) and speciﬁcity
(% of CR) was maximized (Youden's J: Youden, 1950); (Mausbach
et al., 2011).AUC=0.77
0.6
0.4
0.2
Se
ns
iti
vi
ty2.6. Proﬁles for the UPSA-B
Proﬁles were created to show domain- or task-speciﬁc performance
in each group. Themean scoreswere calculated for each task (MAX=1
except for one taskwithMAX=2 in the Finance part), andwere plotted
on a horizontal axis scaled with task numbers.95%CI: 0.70-0.85
0.0
0.0
0.2 0.4
1-Specificity
0.6 0.8 1.0
Fig. 1. ROC curves for UPSA-B Total score.2.7. Correlation analyses
Simple correlations (Pearson’s r) were calculated between the
UPSA-B Total score and the MCCB overall composite and seven
domain scores.3. Results
3.1. Group comparisons
Table 2 presents the statistical results for demographic variables and
the performance on the UPSA-B and the MCCB. Age did not differ be-
tween groups (t=−0.36, df= 143, n.s.) while Education was signiﬁ-
cantly higher for normal controls (t= 10.12, df = 143, p b 0.01). The
UPSA-B Total score (t = 6.80, df = 145, p b 0.01) and the MCCB
composite score (F = 67.30, df = 1, 140, p b 0.01) were signiﬁcantly
higher for normal controls than Main effects of Group and Subscales
of the UPSA-B were signiﬁcant without an interaction effect; normal
controls performed better than patients (F =46.24, df = 1, 145,
p b 0.01) on both Finances and Communication subscales,
and the Finances score was higher than Communication in both groups
(F= 474.18, df= 1, 145, p b 0.01).
Overall, relatively large ESs were obtained (d≥ 0.8), suggesting that
substantial differences existed between normal controls and patients in
measures of both functional capacity (UPSA-B) and neurocognition
(MCCB) (Table 2).
3.2. ROC curve analyses
Fig. 1 illustrates ROC curves for the UPSA-B Total score. AUC of 0.77
(95%CI: 0.70–0.85) was signiﬁcantly greater (p b0.001) than that of no
information (0.50). d’ associated with this curve was estimated as 1.26.
The optimal cut-off point for the Total score (MAX= 100) was esti-
mated as 77.8, at which sensitivity (hit rate) and 1 − speciﬁcity (FA
rate)were 0.67 and0.21, respectively. The results suggest that of all nor-
mal controls, 67% had the UPSA Total score of 77.8 or above, while of all
patients, 89 (=100− 21)% scored below this score.
3.3. Proﬁles of the UPSA-B
Fig. 2 presents proﬁles of UPSA-B scores for normal controls (A) and
patients with schizophrenia (B). Normal controls performed almost
perfectly on the Finances part (Fig. 2A, the left section). Likewise, the pa-
tient group showed better performance on the Finances part (Fig. 2B,
the left section) than the Communication part (Fig. 2B, the right part).
Both normal controls and patients tended to perform poorly on Task
13 (speaking on the phone with a name and an address given by the
13
16
19
0.0
0.5
1.0
1.5
2.0
NC
Finances CommunicationA
B
13
16
190.0
0.5
1.0
1.5
2.0
SCZ
Fig. 2. UPSA-B proﬁles for normal controls (A) and patients with schizophrenia (B). Task
13: Speaking to the phone a name and an address given by a tester. Task 16: Leaving a
voice-mail message to a reschedule of an appointment. Task 19: Remembering prepara-
tions designated by a medical appointment.
141C. Sumiyoshi et al. / Schizophrenia Research: Cognition 1 (2014) 137–143tester), Task 16 (leaving a voice-mailmessage to reschedule an appoint-
ment), and Task 19 (remembering preparations designated by a medi-
cal appointment) (Fig. 2 A, B).
3.4. Correlations between the UPSA-B and the MCCB
Correlations between the MCCB measures and the UPSA-B Total
score scores were presented in Table 3. On the whole, the patient
group yielded relatively larger rs than the normal control groupTable 3
Correlations between the MCCB and the UPSA-B.
MCCB domains and tests NC SCZ
Overall compositea 0.27⁎ 0.35⁎⁎
Speed of Processing Compositeb 0.15 0.25
Trail Making Test
BACS Symbol Coding
Fluency
Working Memory Compositec 0.21 0.36⁎⁎
WMS-II Spatial Span
Letter Number Sequencing
Verbal Learning 0.06 0.36⁎⁎
HVLT-R
Reasoning and Problem solving −0.01 0.20
NAB Maze
Visual Learning 0.19 0.24
BVMT-R
Social Cognition 0.16 −0.10
MSCEIT Managing Emotion
Attention/Vigilance 0.23⁎ 0.27⁎
CPT-IP
NC: normal controls, SCZ: patients with schizophrenia.
⁎ p b0.05.
⁎⁎ p b 0.01.
a The sum of the T scores for seven domains.
b The sum of TMT, BACS SC, and Fluency.
c The sum of WMS III SS and LNS.(Table 3). The MCCB Overall composite, Working Memory composite,
and Verbal Learning in the patient group showedmoderate correlations
(≥0.3) reaching a statistical signiﬁcance. Attention/Vigilance was also
signiﬁcantly correlated with the UPSA-B Total score. in both groups, al-
though the rs were modest (0.23–0.27). The MSCEIT had the weakest
relationship to the UPSA-B Total score, not revealing substantial
correlations (≤0.1) in either group (Table 3).4. Discussion
The principal ﬁndings of the current study are summarized as
follows: (1) the Japanese version of the UPSA-B has good discrimi-
nating power for diagnostically different groups yielding a large
effect size (d ≥ 0.8) and optimal cut-off point (around 80), (2) the
Finance subscale of the UPSA-B was markedly better performed
than the Communication subscale in both healthy adults and pa-
tients, showing poor performances on certain tasks in the
Communication subscale, and (3) Performance on the UPSA-B
Japanese version reﬂected neurocognitive functioning especially in
patients with schizophrenia.
The average score of the UPSA-B Total score of the normal sample
obtained in the current study was above 80, consistent with Leifker
et al. (2010). Given that a majority of the studies from the US and
Europe have reported that the averages of patients fell under 80
(Table 1), and that the optimal cut-off point in the current study was
78.8, it seems to be feasible to set the discriminative point at around
80 (less than 3–4 failures out of 20 tasks). In other words, the point
around here is suggested to be an endpoint for patients with schizo-
phrenia to live and function well in the community.
The disassociation between patients and normal controls found here
was also in accordwith a study in China (McIntosh et al., 2011), yielding
relatively larger effect sizes (d ≥ 0.8). Although the scores of Chinese
samples were lower than other studies (Table 1), this is due to a wide
range of educational attainment in the research participants who were
selected, in order to show that the UPSA-B was sensitive to education
and that patients with low levels of education would have poor perfor-
mance because of both educational and illness related variables
(McIntosh et al., 2011).
In addition to the diagnostically critical point noted above, identiﬁ-
cation of ‘functional milestones’ (e.g. goal lines for achievement in resi-
dential independence or employment) (Mausbach et al., 2011) would
be informative for patients undergoing their rehabilitation. Previous
studies exploring those cut-offs have reported that a score of 60 or
above was able to be used to determine independent- vs. assisted-
living status (Mausbach et al., 2007), and a score of 80 or above was
able to be used to predict employment status (≥20 h/week)
(Mausbach et al., 2011). Itwould be of importance to investigatewheth-
er a similar degree of achievement is required for those functional mile-
stones in westernized Asian countries like Japan.
Aswas suggested by the average score of subscales (Table 2) and the
proﬁle analyses (Fig. 2), the performance on the UPSA-B may vary de-
pending on the domains; ANOVA results indicated that the Finances
subscale was considerably higher than that of the Communication sub-
scale in both the normal and the patient groups. In fact, our normal con-
trols nearly gained the maximum score of 50, suggesting that healthy
adults are expected to be almost perfect in this domain. Previous studies
have also reported that the average of the Finances domain exceeded 40
even in people with schizophrenia (Burton et al., 2013; Mausbach et al.,
2007; Vesterager et al., 2012) (Table 1). Given these discrepant ﬁgures
between the subscales, the Total score on the UPSA-B is preferable for
the purposes of general classiﬁcation of functioning on the part of peo-
ple with schizophrenia. Also, our supplementary analyses showed that
discriminative ability of single subscales alone (Finances: AUC =0.68,
d’ = 1.0; Communication: AUC =0.73, d’ = 1.3) was poorer than that
of theTotal score (AUC =0.77, d’ = 1.3).
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and patients for the Communication subscale. Both groups presented a
relatively low score at memory-demanding tasks (Tasks 13, 16, and 19;
Fig. 2). Our preliminary analysis including university students (N=30,
mean age = 20.6) performed well on those tasks, suggesting that age-
and/or disease-based degradation of memory may account for
poor performance.
The UPSA-B Total score showed a signiﬁcant and moderately good
correlationwith theMCCB Composite score in patientswith schizophre-
nia (r≥30), indicating sensitivity of the Japanese version of the UPSA-B
to overall cognitive functioning in a clinical population.Moreover, in the
patient group, Working memory and Verbal learning, in particular,
showed relatively larger correlations compared to other domains, con-
sistent with a previous report by Burton et al. (2013). Interestingly,
the MSCEIT was excluded from the MCCB composite score in their
study, assuming that social cognition would substantially differ from
neurocognition in terms of the relationship to everyday functioning.
Our result seems to support their assumption, as revealed by the
weakest correlations between the MSCEIT and the UPSA-B measure in
both normal controls and patients (Table 3).
Several issues are worth discussing in order to enhance the utility of
the UPSA-B Japanese version. First, essential psychometric properties,
including test–retest reliability, practice effect, and potential sensitivity
in response to treatment need to be examined. Although previous stud-
ies (Leifker et al., 2010; Velligan et al. in press) have reported the UPSA-
B has good qualities in these aspects, these issues should be replicated
with the Japanese version of the UPSA-B.
Second, stratiﬁed cut-off points according to types of functional re-
covery (e.g. residential status, employment) (Mausbach et al., 2011)
or demographic variables (e.g. age) would be worth investigating. Re-
garding the latter, as noted before, healthy adults have been shown to
perform well (≥80) on the UPSA-B (Leifker et al., 2010). Similarly, a
study with the full version of the UPSA (Harvey et al., 2010) has report-
ed that basic daily-living activities were relatively unaffected by age,
based on data from healthy elderly population. Despite those facts, our
preliminary data indicate that younger subjects (university students)
performed better than middle-aged workers for the Communication
subscale (students = 38.5, workers = 33.4). This suggests that the ex-
ecution of this battery might be age-dependent to a certain degree. Be-
sides, the normal achievement might become less demanding as a
person gets older; elderly people may not be expected to be as equally
efﬁcient as younger people who are generally more productive in
work or social activities. Whether the performance on the UPSA-B is af-
fected by age or socio-economical requirementswarrants further inves-
tigations. Results from such studies may indicate a need for stratiﬁed
standard scores or cut-offs.
Finally, as noted in a previous study (Vesterager et al., 2012),
updated versions with or without supplemental tasks/props would
facilitate the application to subjects with a wide range of demographic
backgrounds.
To conclude, our study has presented data which conﬁrmed the util-
ity of the Japanese version of the UPSA-B. The battery has a good dis-
criminative validity in differentiating patients with schizophrenia from
a healthy middle-aged population, consistent with previous studies
using elderly samples. Further, the responsiveness to cognitive function-
ing in patients with schizophrenia adds support to the utility of the
UPSA-B as a co-primary measure in westernized countries like Japan.Role of Funding Source
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